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ABSTRACT 
Objective: Oral administration of rizatriptan benzoate shows poor bioavailability due to first pass metabolism, which can be avoided by nasal 
administration of drugs. Additionally, the nasal administration provides faster onset of action, which is desired to get relief from the intense pain of 
a migraine. The present research work was emphasised on design, development and evaluation of mucoadhesive microspheres for nasal delivery of 
rizatriptan benzoate through a systematic approach. 
Methods: The microspheres of rizatriptan benzoate were prepared by the w/o/w double emulsion solvent diffusion method using the non-aqueous 
medium. Critical formulation and process parameters were identified through preliminary trial batches and 2[4-1] fractional factorial design was 
employed using polymer concentration (X1:2-5%), drug to polymer ratio (X2:1:2-1:6), amount of liquid paraffin (X3:100-200 ml) and the amount of 
magnesium stearate (X4:100-150 mg) as independent variables. 
Results: Design batches were evaluated for percent yield (50-78%), percent entrapment efficiency (62-85%), drug loading (7.5-30%), % 
mucoadhesion (47-75%) and drug release at 6 h (44-78%). Scanning electron microscopic (SEM) study showed that microspheres were of 50 µm in 
size and spherical in shape with a smooth surface. The optimised batch (D10) showed 85% entrapment efficiency and 66.6% drug release within 6 
h. The developed microspheres could be used to deliver rizatriptan benzoate through nasal administration for treatment of a migraine. 
Conclusion: The developed microspheres can be considered as a promising system for nasal delivery system of rizatriptan benzoate 
Keywords: Rizatriptan benzoate, Ethylcellulose, Mucoadhesive microspheres, Nasal route 
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INTRODUCTION 
A migraine is a most common disease affecting more in women as 
compared to men amongst the victim population. The goal of managing 
migraine is to reduce its occurrence. The migraine attack can be 
controlled by changing lifestyle as well as by drug therapy. Several drugs 
are utilised in the management of a migraine which includes beta-
blocking agents, Ca channel blockers, tricyclic antidepressants and 
anticonvulsants. Over-the-counter analgesics and prescription drugs are 
available in the market for the painful condition of a migraine [1]. 
The drugs used in the treatment of migraine are generally 
administered by the peripheral route. Although the oral route of 
administration is most popular and stands on the top of all other 
routes, but it also has a few limitations like first pass metabolism 
and drug degradation at various pH conditions of GIT. However, now 
a day’s other routes like transdermal, pulmonary, nasal, etc. are 
gaining popularity to deliver challenging molecules to its site of 
action. Among all, nasal route now being watched as the preferred 
route of administration for brain targeting. Nasal route protects 
drugs and biomolecules from susceptible enzymatic or acidic 
degradation, can deliver drugs directly to the brain via olfactory lobe 
and eliminate first pass metabolism. Nasal cavity also has highly 
vascularized epithelial layer and enough absorption area. Brain 
targeting further can reduce the dose and dose-related side effects. 
The various pathways responsible for drug transport in the nasal 
mucosa include carriers mediated transport, passive diffusion, 
transcytosis and transport through tight junctions. Due to the direct 
delivery of drug to brain via olfactory region, the nasal route 
provides faster onset of action which is very essential for getting 
relief from an intense migraine headache [2-6]. 
The microsphere is an important particulate drug delivery system due to 
their small size and efficient carrier function. Microspheres provide 
several advantages such as improved efficacy, reduced toxicity, 
improved patient compliance and convenience [7]. Ethyl cellulose (EC) is 
a water-insoluble polymer with the excellent safety profile and wide 
acceptance. [8]. It is a low viscosity grade polymer used to control drug 
release by coating compressed tablets or microspheres [9].  
Rizatriptan benzoate is an orally active serotonin 5-HT receptor agonist 
that selectively binds to the 5-HT receptor. It is available in the market as 
5 mg and 10 mg orally disintegrating tablet. It is considered as a serious 
prospect for development of mucoadhesive nasal microspheres due to 
its short plasma half-life of 4 h and low oral bioavailability (40%) due to 
extensive first pass metabolism by hepatic enzymes [10-12]. Currently, it 
is available in tablet form, and we have explored the nasal route to 
overcome above mentioned challenges. 
The purpose of the present research work was to develop and 
optimise the ethyl cellulose based microspheres for nasal 
administration of rizatriptan benzoate. The systematic approach 
was utilised for the development of microspheres by the w/o/w 
double emulsion method and for its detailed in vitro evaluation. This 
system may achieve a therapeutic effective concentration of drug in 
the systemic circulation over an extended period of time with better 
patient compliance [13]. 
MATERIALS AND METHODS 
Materials 
Rizatriptan benzoate was obtained as a gift sample from the Torrent 
Research Center, Ahmedabad (India). Ethyl cellulose (45 cp) was 
obtained as a gift sample from the Cadila Healthcare Ltd., Ahmedabad 
(India). Light liquid paraffin was purchased from Finar Ltd., Ahmedabad 
(India) and Pectin from Hi-media Ltd., Mumbai (India). All the other 
chemicals and reagents used in this study were of analytical grade. 
Methods 
Preparation of rizatriptan benzoate microspheres 
Microspheres were prepared by the w/o/w double emulsion method. 
1062.5 mg of ethylcellulose (45 cp) was dissolved in a blend of light 
liquid paraffin and n-hexane. Then212.5 mg of rizatriptan benzoate 
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was added to the above ethyl cellulose solution slowly with stirring 
and emulsified with an aqueous medium containing a magnesium 
stearate (100 mg) as a stabiliser. The mixture was stirred for 3-4 h in 
order to remove organic solvents. The resulting dispersion was 
filtered, and microspheres were washed twice with distilled water. 
Finally, microspheres were air dried for 24 h and then stored in a 
tightly closed container until further use [14, 15]. 
Optimisation using experimental design 
Based on various trial batches, polymer concentration, a drug to 
polymer ratio, the volume of liquid paraffin and amount of 
magnesium stearate was considered as important variables affecting 
formulation parameters. The design of experiments (DOE) approach 
was used to study the relationship between the process variables 
and output. A 2[4-1] fractional factorial experimental design was 
employed to study interactions among the variables. The 
independent variables were polymer concentration 1 to 3% (X1), 
drug to polymer ratio 1:2 to 1:6 (X2), volume of liquid paraffin 100 to 
200 ml (X3) and the amount of magnesium stearate 100 to 150 mg 
(X4)(as shown in table 1) and the dependent variables were % 
practical yield, particle size, % mucoadhesion, %entrapment 
efficiency and % drug loading [16]. 
 
Table 1: Transformed values for 24-1 factorial design batches 
Batch No Transformed factors 
 X1 X2 X3 X4 
D1 -1 -1 -1 -1 
D2 +1 +1 -1 -1 
D3 +1 -1 +1 -1 
D4 -1 +1 +1 -1 
D5 +1 -1 -1 +1 
D6 -1 +1 -1 +1 
D7 -1 -1 +1 +1 
D8 +1 +1 +1 +1 
 Actual value 
Levels X1 X2 X3 X4 
(-1) 2 % 1:2 100 100 
(+1)  5 % 1:6 200 150 
 
Data analysis, statistical optimisation and model validation 
Analysis of variance (ANOVA) was utilised for statistical validation of 
polynomial equations generated by Design expert software (Stat-Ease 
Inc., ver. 8.0.1, Minneapolis, USA). An overlay plot was used to 
generate design space and select optimised batch. Three-dimensional 
response surface plots were generated to validate the model [17]. 
Characterization microspheres 
Production yield 
The percent yield of microsphere was calculated based on the 
amount of drug and polymer used for the formulation of 
microspheres. The yield was calculated by using the following 
equation [18]. 
Percent yield = 


*10 
Where W1 = weight of dried microspheres 
W2 = weight of rizatriptan benzoate and ethyl cellulose 
Particle sizes analysis 
Particle size analysis of rizatriptan benzoate is loaded ethyl cellulose 
microspheres was determined by an optical microscope (Unico, IP 
730, NJ, USA). A little amount of dry microspheres was dispersed in 
cyclohexane (5 cc) (cyclohexane was selected due to insolubility of 
polymer and drug in it). Then the suspension was sonicated for 5 s. A 
small drop of suspension, thus obtained was placed on a clean glass 
slide. The slide containing ethyl cellulose microspheres was mounted 
on the stage of the microscope, and the diameter of molecules was 
evaluated utilising a calibrated ocular micrometre. [19, 20]. 
In vitro mucoadhesion studies 
The mucoadhesive property of microspheres was determined by 
mucoadhesion apparatus (fabricated in the laboratory). For study 
purposes, the sheep nasal mucosa was isolated by cutting nose bone 
with the help of a bone cutting tool. Then mucosal portion was 
separated slowly from bone by using blunt forceps within 2 h of 
sacrifice and washed with isotonic saline solution. Accurately 
weighed the quantity of microspheres was placed on the mucous 
membrane, which was confiscated over a plate and phosphate buffer 
pH 6.6 (37 °C) was appended at a rate of 2 ml/min and flow was 
regulated by means of the burette. The percent mucoadhesion was 
determined by looking at the amount of microspheres adhered to 
the mucosa and total amount of microspheres initially applied to 
mucous. The percent mucoadhesion was calculated utilising the 
following equation after 2 h [21]. 
% Mucoadhesion = 
	    	 
	 	  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 	  
 *100 
Drug loading and entrapment efficiency 
Fifty mg of microspheres was taken and crushed in a glass mortar 
and pestle. The resulting powdered microspheres were suspended 
in 50 ml phosphate buffer (pH 6.6). The mixture was stirred using 
the magnetic stirrer for 24 h. The solution was strained and the 
filtrate was analysed spectrophotometrically (UV 1800, Shimadzu, 
Japan) at 278 nm. The drug loading and entrapment efficiency (%) 
was calculated by applying the following equations [22, 23]. 
Drug loading= 
Amount of drug in microspheres
Amount of microspheres formed
 *100 
Entrapment Efficiency = 
	    
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 	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 *100 
Scanning electron microscopy (SEM) 
The surface characteristic of the optimised batch (D10) was analysed 
by scanning electron microscope (SEM). The microspheres were 
placed on double-sided tape that had previously been secured on 
aluminium stubs, and the microspheres were observed by scanning 
electron microscope (JSM 6510 LV, JEOL DATUM Ltd., Japan) operated 
at a voltage of 10 kV and magnification of 3000x [24]. 
Differential scanning calorimetry (DSC) 
The thermal nature of rizatriptan, blank microspheres and rizatriptan-
loaded microspheres (Batch D10) was determined using differential 
scanning calorimeter (DSC 4000, Perkin Elmer, USA). Five mg of 
rizatriptan microspheres was accurately weighed and hermetically 
sealed in aluminium pans. Thermograms were obtained by heating 
samples at a constant rate of 10 ˚C/min and the over the temperature 
interval of 30–300 ˚C under a nitrogen purge of 20 ml/min [25]. 
In vitro diffusion study 
Multiple Franz's diffusion cell (12 ml capacity; 10.17 cm2 area) 
(Orchid scientific, FDC-06, India) was used to study the in vitro 
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diffusion of the optimised microsphere batch (D10) across the sheep 
nasal mucosa (thickness: ~100 µ) as a permeation barrier. The 
microspheres equivalent to 5 mg of rizatriptan benzoate was 
spreaded over the membrane into donor compartment already 
containing 3 ml simulated nasal fluid (monosodium phosphate 
anhydrous (7.5 mmol), disodium phosphate anhydrous (3 mmol), 
sodium chloride (150 mmol), potassium chloride (40 mmol) and 
calcium chloride (5 mmol)) [26] and receptor compartment was 
filled with phosphate buffer solution pH 6.6 (12 ml) (pH same as 
that of nasal cavity). The temperature was maintained at 37±0.5 °C 
with the aid of a circulating water bath. Samples were periodically 
withdrawn at 5 min, 15 min, 1 h, 2 h, 4 h, and 6 h and replaced with 
the same quantity of fresh buffer solution. The samples were filtered 
and examined using a spectrophotometer at 278 nm [27]. 
RESULTS AND DISCUSSION 
Holding in mind industrial preference, microspheres was developed 
using water as an external phase by a solvent evaporation method in 
preliminary work. As rizatriptan benzoate is hydrophilic in nature, it 
is likely to partition into the aqueous medium, leading to low 
entrapment efficiency (<20%) even after optimisation of process 
and formulation parameters. Hence, the effort was made to 
encapsulate rizatriptan benzoate with sufficiently high entrapment 
efficiency by a W/O/W double emulsion method using a non-
aqueous processing medium. It is a simple and rapid method for 
fabrication of microspheres. 
Various formulation factors like polymer concentration, a drug to 
polymer ratio, the concentration of stabiliser as well as process 
parameters like stirring speed, stirring time and volume of external 
phase were studied during preliminary trials (Data not shown). It is 
reported that magnesium stearate can be utilised as a stabiliser and 
it may cause an impingement on the size as well as drug release 
from microspheres [28]. It was likewise discovered that polymer 
concentration, a drug to polymer ratio and concentration of 
stabiliser were found equally significant components of product 
characteristics. Hence, these four factors were selected for 
optimisation using 24-1 fractional factorial design. 
Preparation of microspheres 
Eight batches were prepared by the W/O/W double emulsion 
method as per factorial design, in which polymer concentration 
(X1:2-5%), drug to polymer ratio (X2:1:2-1:6), amount of liquid 
paraffin (X3:100-200 ml), amount of magnesium stearate (X4:100-
150 mg) were selected as independent variables and % practical 
yield (Y1), particle size (Y2), % mucoadhesion (Y3), % entrapment 
efficiency (Y4) and % drug loading (Y5) of the microspheres were 
taken as the dependent variables (table1 and 2). Amongst all the 
responses, percent entrapment efficiency, % mucoadhesion and 
drug diffusion at 6 h were treated using design expert software. 
Characterization of microspheres 
Production yield 
The yield of production was in the range 50-78 %. The production 
yield depends on the quantity of drug loaded into the microspheres. 
Particle size 
The mean particle size of microspheres ranged from 42 to 50 μm 
(table 2), indicated narrow particle size distribution. The narrow 
particle size distribution was considered as a prerequisite for nasal 
administration. It has been reported that particles smaller than 1 mm 
directly pass the nasal cavities with the inspired air, whereas particles 
larger than 10 μm deposits at the anterior parts of the nose [24]. 
In vitro mucoadhesion 
In vitro mucoadhesion studies give information about adhesive 
properties of the developed formulation at the site of absorption. 
The results showed that the microspheres remained adhered on the 
nasal mucosa for required time. The proportion of the adhered 
microspheres was expressed as percentage mucoadhesion. For 
optimised batch D10, percentage mucoadhesion was found to be 
67%. Increase in concentration of ethyl cellulose further increased 
the mucoadhesion. Most of the studies showed that most important 
condition for a good mucoadhesion is the high flexibility of polymer 
structure and presence of polar functional groups. The cross-linked 
microspheres are more rigid as compared to non-cross-linked 
microspheres. In vitro mucoadhesion studies cannot mimic in vivo 
condition but in vitro–in vivo correlation can be established. [29]. 
Drug loading and entrapment efficiency 
The encapsulation efficiency determines the percentage of 
encapsulated drug with respect to the total drug introduced into the 
polymer solution. The concentration of polymer showed a 
significant difference in encapsulation efficiency. 
The encapsulation efficiency was in the range of 62.55 to 95.77 (table 
2). The study showed that increase in the polymer concentration 
resulted into higher encapsulation efficiency. This might be due to the 
higher viscosity of the polymer solutions reduced the escaping of drug 
into the external phase, which resulted into higher drug entrapment. 
The entrapment efficiency of batch D10 was 84.66% [2].  
Drug loading was found to be between 7 to 30 %, is inversely 
proportional to polymer concentration and also to the drug to polymer 
ratio (table 2). 
Scanning electron microscopy 
The surface morphology of optimised formulation was examined by 
scanning electron microscopy as shown in fig. 1.  
 
 
Fig. 1: SEM image of optimised batch 
 
Microspheres were spherical in shape and possessed a smooth 
surface; such morphology shows a good deposition pattern in the 
nasal cavity. The further majority of particles were having a particle 
size less than 50 µm, which is the requisite of the nasal formulation. 
 
Table 2: Evaluation results of microspheres 
Batch No % Production yield Particle size % Mucoadhesion PEE % Drug loading 
D1 55.12±4.1 42.87±0.88 47±2.31 68.09±0.25 25.91±0.78 
D2 50.58±5.3 49.10±0.33 68±1.75 86.18±0.23 12.27±0.65 
D3 78.00±4.3 47.05±1.45 75±1.02 90.21±0.85 27.84±1.03 
D4 76.47±3.3 44.76±.0.55 52±0.89 66.68±0.56 7.50±0.89 
D5 54.56±4.2 46.70±0.25 70±2.22 95.77±0.73 30.31±0.75 
D6 68.91±2.3 43.68±0.18 55±2.14 70.85±0.69 8.65±0.58 
D7 64.12±3.5 41.63±1.25 51±1.81 62.65±0.65 17.35±1.02 
D8 70.04±4.9 48.56±2.10 72±1.85 80.17±0.35 10.82±2.41 
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Differential scanning calorimetry 
The thermogram of rizatriptan benzoate exhibited a sharp 
endothermic peak at 196.05 °C, signifying its melting point which 
was reported in the literature fig.2a. Characteristic peaks of 
rizatriptan benzoate were disappeared in the drug-loaded 
microspheres. This indicates that rizatriptan benzoate was 
uniformly dispersed and encapsulated in the polymeric 
microspheres show an ever peak of ethyl cellulose was observed at 
183.63 °C fig. 2b. 
 
 
Fig. 2a: DSC spectra of rizatriptan benzoate 
 
 
Fig. 2b: DSC spectra of rizatriptan benzoate loaded microspheres 
 
In vitro diffusion 
The in vitro diffusion study of a batch D10 of rizatriptan benzoate 
loaded microspheres was carried out using the sheep nasal mucosa. 
The result of in vitro diffusion study is represented in fig. 3. 
 
 
Fig. 3: In vitro diffusion study of optimised batch (D10) (n=3) 
 
The percent drug permeated at 6 h was 66.6% which indicate 
incomplete drug diffusion. The absorption will depend on the 
retention of microspheres in the nasal cavity.  
Statistical Interpretation 
A) For percent entrapment efficiency (PEE) 
The polynomial equation for PEE was generated using multiple 
linear regression analysis. The equation was derived as follows:  
PPE = 77.55 + 10.58 ∗ X1 − 1.53 ∗ X2 − 2.67 ∗ X3 − 0.24 ∗ X4
− 3.33 ∗ X1X3 + 10.17 ∗ X1X3 + 0.18 ∗ X1X4 
The results indicated that the concentration of polymer has a high 
positive impact on entrapment of the drug. Therefore with increased 
in concentration of polymer, PEE was also increased (fig. 4). The 
drug to polymer ratio had shown the negative impact on PEE; it may 
be due to a higher proportion of the drug in comparison with the 
polymer. The volume of light liquid paraffin, as well as the amount of 
stabilizer also, has shown negative effects on PEE. Further, the 
regression statistics showed that the R2value 0.9998, which 
indicates a good fit. 
 
 
Fig. 4: 3D-surface graph for percentage entrapment efficiency 
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B) % CPR for 6 h 
The polynomial equation for drug release was also generated using 
multiple linear regression analysis as under:  
% CPR = 77.81 − 18.31 ∗ X1 − 2.13 ∗ X2 + 1.75 ∗ X3 − 5.93 ∗ X4
− 2.59 ∗ X1X2 + 
1.65 ∗ X1X3 + 3.70 X1X4 
The concentration of polymer had a negative significant effect on % 
CPR after 6hdue to release retarding nature of polymer (fig. 5). 
Further increased in the proportion of drug with respect to polymer 
also reduced the release rate of rizatriptan benzoate. 
Hydrophobicity of magnesium stearate might also be responsible for 
retardation in drug release indicated by negative signs of the 
coefficient. The volume of liquid paraffin had a positive effect on 
drug release which might be due to larger volume available for the 
dispersion, resulted into a smaller size of microspheres with higher 
surface area. Further, the regression statistics showed that the 
R2value was 0.9424, which indicated a good fit.  
 
 
Fig. 5: 3D-surface graph of % CPR at 6thh 
 
C) Percent mucoadhesion (% MA) 
The polynomial equation was generated for mucoadhesion using 
multiple linear regression analysis. Full model equation was as 
follows:  
% MA = +61.25 + 10.00 ∗ X1 + 0.50 ∗ X2 + 1.25 ∗ X3 + 0.75 ∗ X4
− 1.75 ∗ X1X2 + 1.00 ∗ X1X3 − 1.00 X1X4  
The results indicated that the concentration of polymer had a 
significant positive impact on % mucoadhesion (fig. 6). Hence, an 
increase in the concentration of polymer had resulted into higher 
mucoadhesion. The remaining three factors showed the little 
positive effect on mucoadhesion indicated by a small value of the 
coefficients. Further regression statistics had shown that the R2value 
was 0.9814, which signifies a good fit.  
 
Fig. 6: 3D-surface graph for % mucoadhesion 
 
FDA recommends the use of a systematic approach for formulation 
development and hence, the output can help to justify minor post-
approval changes in the formulation if required. Hence, to identify 
the design space, overlay curve was drawn considering percent 
entrapment efficiency at least above 80%, drug release at 6 h from 
65% to 75% and more than 60% mucoadhesion as required, 
responses as shown in fig. 7. 
 
 
Fig. 7: Overlay plot 
 
This curve indicates that the concentration of a polymer in the range 
of 2.25% to 2.75% and drug to polymer ratio in the range of 1:2 to 
1:6, low level of volume of liquid paraffin and magnesium stearate, 
resulted into the fulfilment of all set criteria.  
Two checkpoint batches suggested by design of experiment 
approach were prepared and evaluated. The results of the batches 
were predicted from polynomial equations generated from the 
coefficients of 24-1 fractional factorial design. Predicted responses 
were compared with practically calculated responses (table 3). 
Predicted responses were similar to practical values which further 
validated the derived mathematical models. Batch D10 was selected 
as optimised batch as it was well within generated design space and 
showed good percentage entrapment and mucoadhesion which is 
desired for nasal drug delivery. 
 
Table 3: Evaluation of checkpoint batches 
Batch no Composition Predicted values Observed value 
Code value Actual value 
X1 X2 X1 X2 PEE % CPRAt 6 h % Muco PEE % CPRAt 6 h % Muco 
D9 -0.5 -0.5 2.75 1:3 73.02 88.02 56.0 70.46 85.05 54 
D10 +0.5 +0.5 4.25 1:5 82.07 67.59 66.5 84.66 66.61 67 
 
The developed microspheres can be delivered through powder 
insufflators, or microspheres can further be converted into either 
spray or in situ gel to facilitate delivery via the nasal route. This shall 
be followed by the studies using a suitable animal model to claim 
brain targeting. 
CONCLUSION 
The article demonstrated the systematic approach for the 
development of microspheres containing rizatriptan benzoate using 
ethyl cellulose as a polymer. By selecting and evaluating the process 
and product parameters at the appropriate level, it is possible to 
prepare microspheres with desired properties; such as uniform 
particle size distribution, high entrapment efficiency and improved 
surface properties. The most prominent advantage of the 
microspheres is that it is a free flowing powder suitable for nasal 
administration using powder, insufflators; this feature is useful for 
the convenience of administration for patients and maintaining the 
accuracy of drug dosing. This study concludes that the developed 
microspheres can be considered as a promising nasal delivery 
system for the administration of rizatriptan benzoate. 
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